SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy’s buys GSK’s oral penicillin facility in US

24 Nov 2010 Evaluate

Dr Reddy’s Laboratories has bought GlaxoSmithKline’s oral penicillin facility and products in the US for an undisclosed sum. The transaction is expected to close within the first half of calendar year 2011.As per the agreement; GSK will transfer ownership of its penicillin manufacturing site in Bristol, Tennessee, and rights for the Augmentin and Amoxil brands in the US to DRL. The rights for the non-US markets will, however, remain with GSK. 

This acquisition allows DRL to enter the US penicillin-containing antibacterial market segment and serve the needs of its customers. This is in line with company’s strategy to significantly scale up our generics business in North America, while providing an opportunity to explore additional synergy with our other businesses.

According to IMS data, Augmentin and Amoxil brands contributed revenues of around $73 million to GSK in FY09. However, DRL is unlikely to garner such sales from these brands in future due to strong competition from other generics in the segment. The entire segment clocked sales to the tune of around $750 million for 12 months to August, 2010. crackcrack

Dr. Reddys Lab Share Price

1235.40 14.15 (1.16%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×